{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:42:20Z","timestamp":1791333740719,"version":"4.3.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T00:00:00Z","timestamp":1680393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013272","name":"Institute for Frontier Materials, Deakin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1113293"],"award-info":[{"award-number":["1113293"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1117766"],"award-info":[{"award-number":["1117766"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2008913"],"award-info":[{"award-number":["2008913"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000943","name":"Commonwealth Scientific and Industrial Research Organisation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-COVID19RF-003"],"award-info":[{"award-number":["MOH-COVID19RF-003"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health and Aged Care, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["1173871"],"award-info":[{"award-number":["1173871"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DE210100705"],"award-info":[{"award-number":["DE210100705"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ebiom.2023.104574","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T17:19:04Z","timestamp":1683220744000},"page":"104574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine"],"prefix":"10.1016","volume":"92","author":[{"given":"Georgia","family":"Deliyannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Gherardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinn Yi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Grimley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ellenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3754-2642","authenticated-orcid":false,"given":"Francesca L.","family":"Mordant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2493-3465","authenticated-orcid":false,"given":"Julie","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Wah","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mason","family":"Littlejohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6336-6657","authenticated-orcid":false,"given":"Jasper","family":"Fuk-Woo Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4511-2888","authenticated-orcid":false,"given":"Zhi-wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airn E.","family":"Hartwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-4849","authenticated-orcid":false,"given":"Elizabeth","family":"Vincan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Torresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kedzierska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-3308","authenticated-orcid":false,"given":"Colin W.","family":"Pouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom P.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-fa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-4891","authenticated-orcid":false,"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam K.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-8241","authenticated-orcid":false,"given":"Sharon R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy W.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent","family":"Munro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian F.J.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3009-5472","authenticated-orcid":false,"given":"Dale I.","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7830","key":"10.1016\/j.ebiom.2023.104574_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.ebiom.2023.104574_bib2","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10249","key":"10.1016\/j.ebiom.2023.104574_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ebiom.2023.104574_bib4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104574_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"24","key":"10.1016\/j.ebiom.2023.104574_bib7","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104574_bib8","first-page":"269","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"7","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10328","key":"10.1016\/j.ebiom.2023.104574_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104574_bib10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"10.1016\/j.ebiom.2023.104574_bib11","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a fourth dose of BNT162b2 against omicron in Israel","volume":"386","author":"Bar-On","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.ebiom.2023.104574_bib12","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of Covid-19 mRNA vaccine against omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104574_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071502","article-title":"Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study","volume":"378","author":"Grewal","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ebiom.2023.104574_bib14","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5","author":"Wang","year":"2022603","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104574_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41577-021-00556-5","article-title":"Will SARS-CoV-2 variants of concern affect the promise of vaccines?","volume":"21","author":"Gupta","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"10.1016\/j.ebiom.2023.104574_bib16","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104574_bib17","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104574_bib18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104574_bib19","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/s41591-022-02031-7","article-title":"Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2\/3 trial","volume":"28","author":"Chalkias","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.ebiom.2023.104574_bib20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A\u00a0bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendonca","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104574_bib22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis with COVID-19 mRNA vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","article-title":"From original antigenic sin to the universal influenza virus vaccine","volume":"39","author":"Henry","year":"2018","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib24","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/s41467-021-23977-1","article-title":"Immunological imprinting of the antibody response in COVID-19 patients","volume":"12","author":"Aydillo","year":"2021","journal-title":"Nat Commun"},{"issue":"6603","key":"10.1016\/j.ebiom.2023.104574_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq1841","article-title":"Immune boosting by B.1.1.529 (omicron) depends on previous SARS-CoV-2 exposure","volume":"377","author":"Reynolds","year":"2022","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104574_bib26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.it.2021.09.001","article-title":"Immune imprinting and SARS-CoV-2 vaccine design","volume":"42","author":"Wheatley","year":"2021","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104574_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJMc2206711","article-title":"Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine","volume":"387","author":"Launay","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41392-022-01123-7","article-title":"Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"10.1016\/j.ebiom.2023.104574_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00558-22","article-title":"Shared N417-dependent epitope on the SARS-CoV-2 omicron, beta, and delta plus variants","volume":"96","author":"Moyo-Gwete","year":"2022","journal-title":"J\u00a0Virol"},{"issue":"600","key":"10.1016\/j.ebiom.2023.104574_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi9915","article-title":"Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection","volume":"13","author":"Greaney","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41541-021-00393-6","article-title":"Scientific rationale for developing potent RBD-based vaccines targeting COVID-19","volume":"6","author":"Kleanthous","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104574_bib32","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104574_bib33","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/v14092061","article-title":"Receptor-binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2","volume":"14","author":"Farrell","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ebiom.2023.104574_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.biomaterials.2017.05.018","article-title":"PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8+ T cell responses","volume":"137","author":"Sekiya","year":"2017","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104574_bib35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A\u00a0simple method for estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104574_bib36","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A\u00a0SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"16","key":"10.1016\/j.ebiom.2023.104574_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150012","article-title":"Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay","volume":"6","author":"Lopez","year":"2021","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.ebiom.2023.104574_bib38","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMoa2108453","article-title":"Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors","volume":"385","author":"Tan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104574_bib39","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","article-title":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden syrian hamster model: implications for disease pathogenesis and transmissibility","volume":"71","author":"Chan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104574_bib40","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104574_bib41","doi-asserted-by":"crossref","first-page":"105259","DOI":"10.1016\/j.isci.2022.105259","article-title":"Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2","volume":"25","author":"Pymm","year":"2022","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104574_bib42","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/ni.3298","article-title":"The burgeoning family of unconventional T cells","volume":"16","author":"Godfrey","year":"2015","journal-title":"Nat Immunol"},{"issue":"19","key":"10.1016\/j.ebiom.2023.104574_bib43","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101918118","article-title":"Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice","volume":"118","author":"Pymm","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7830","key":"10.1016\/j.ebiom.2023.104574_bib44","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A\u00a0vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104574_bib45","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A\u00a0universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib46","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/22221751.2021.1921621","article-title":"A\u00a0novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters","volume":"10","author":"Zhang","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib47","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1080\/22221751.2022.2088406","article-title":"Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104574_bib48","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.vaccine.2022.01.043","article-title":"Phase I interim results of a phase I\/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452","volume":"40","author":"Janssen","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104574_bib49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.ebiom.2023.104574_bib50","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ebiom.2023.104574_bib51","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ebiom.2023.104574_bib52","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104574_bib53","doi-asserted-by":"crossref","first-page":"914167","DOI":"10.3389\/fimmu.2022.914167","article-title":"A\u00a0complementary union of SARS-CoV2 natural and vaccine induced immune responses","volume":"13","author":"Torresi","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104574_bib54","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","author":"Roltgen","year":"2022","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.ebiom.2023.104574_bib55","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.vaccine.2023.02.057","article-title":"A randomized phase I\/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452","volume":"41","author":"Feitsma","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib56","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","article-title":"RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"10.1016\/j.ebiom.2023.104574_bib57","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","article-title":"Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults","volume":"386","author":"Dai","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104574_bib58","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1039\/D1CB00200G","article-title":"A\u00a0COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles","volume":"3","author":"Santana-Mederos","year":"2022","journal-title":"RSC Chem Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib59","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/22221751.2021.1951126","article-title":"Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Liao","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib60","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12985-021-01737-3","article-title":"Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice","volume":"19","author":"Song","year":"2022","journal-title":"Virol J"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104574_bib61","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/all.15305","article-title":"Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants","volume":"77","author":"Gattinger","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.ebiom.2023.104574_bib62","doi-asserted-by":"crossref","first-page":"101383","DOI":"10.1016\/j.eclinm.2022.101383","article-title":"Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA study)","volume":"46","author":"Hernandez-Bernal","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"6606","key":"10.1016\/j.ebiom.2023.104574_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq0839","article-title":"Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models","volume":"377","author":"Cohen","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib64","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41467-021-21665-8","article-title":"Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques","volume":"12","author":"Tan","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104574_bib65","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41423-021-00658-z","article-title":"Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice","volume":"18","author":"Sun","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104574_bib66","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/emmm.201201379","article-title":"Fc-fusion proteins: new developments and future perspectives","volume":"4","author":"Czajkowsky","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104574_bib67","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib68","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1038\/s41467-022-34297-3","article-title":"Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice","volume":"13","author":"Ashhurst","year":"2022","journal-title":"Nat Commun"},{"issue":"6548","key":"10.1016\/j.ebiom.2023.104574_bib69","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.abg8985","article-title":"Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2","volume":"372","author":"Low","year":"2021","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104574_bib70","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.2100195","article-title":"Conserved and novel mouse CD8 T cell epitopes within SARS-CoV-2 spike receptor binding domain protein identified following subunit vaccination","volume":"206","author":"Davenport","year":"2021","journal-title":"J\u00a0Immunol"},{"issue":"7830","key":"10.1016\/j.ebiom.2023.104574_bib71","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104574_bib72","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423001391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423001391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:23:56Z","timestamp":1762457036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423001391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":72,"alternative-id":["S2352396423001391"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104574","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.08.05.22278425","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104574"}}